Edwards Lifesciences (EW) Cash & Current Investments (2009 - 2026)

Edwards Lifesciences' Cash & Current Investments history runs 18 years deep, the most recent figure standing at $3.7 billion for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 5.82% year-over-year to $3.7 billion; the TTM figure through Mar 2026 stood at $3.7 billion (down 5.82% YoY), while the FY2025 annual figure was $4.2 billion, up 6.3% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $3.7 billion, down from $4.2 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $4.4 billion in Q3 2024, with the low at $512.2 million in Q4 2023.
• The 5-year median for Cash & Current Investments is $1.9 billion (2023), against an average of $2.5 billion.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments tumbled 57.59% in 2023, then surged 676.24% in 2024.
• Edwards Lifesciences' Cash & Current Investments stood at $1.2 billion in 2022, then sank by 57.59% to $512.2 million in 2023, then soared by 676.24% to $4.0 billion in 2024, then increased by 6.3% to $4.2 billion in 2025, then decreased by 13.13% to $3.7 billion in 2026.
• Business Quant data shows EW's Cash & Current Investments at $3.7 billion in Q1 2026, $4.2 billion in Q4 2025, and $3.8 billion in Q3 2025.